Indivior

Indivior Announces Q1 2024 Financial Results

Retrieved on: 
星期四, 四月 25, 2024
Webcast, EST, Indivior

SLOUGH, United Kingdom and RICHMOND, Va., April 25, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024.

Key Points: 
  • SLOUGH, United Kingdom and RICHMOND, Va., April 25, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024.
  • The earnings release, investor presentation and webcast are available at www.indivior.com .
  • There will be a live webcast presentation at 13:00 BST (8:00 am EST) hosted by Mark Crossley, CEO.
  • Participants may access the presentation telephonically by registering with the following link: https://register.vevent.com/register/BI2351ee9819db40d1a28c31f75cece519

Indivior Announces Q1 2024 Financial Results

Retrieved on: 
星期四, 四月 25, 2024
Webcast, EST, Indivior

SLOUGH, United Kingdom and RICHMOND, Va., April 25, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024.

Key Points: 
  • SLOUGH, United Kingdom and RICHMOND, Va., April 25, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024.
  • The earnings release, investor presentation and webcast are available at www.indivior.com .
  • There will be a live webcast presentation at 13:00 BST (8:00 am EST) hosted by Mark Crossley, CEO.
  • Participants may access the presentation telephonically by registering with the following link: https://register.vevent.com/register/BI2351ee9819db40d1a28c31f75cece519

Brighthouse Financial Appoints Michael J. Inserra and Lizabeth H. Zlatkus to Board of Directors

Retrieved on: 
星期二, 四月 9, 2024
Professional Services, Other Professional Services, Insurance, Finance, Asset Management, Personal Finance, Brighthouse Financial, Indivior, Inserra Supermarkets, Risk management, Ernst & Young, The Hartford, EY, Audit committee, Lisabeth, Moore Capital Management, Retirement, Management

Brighthouse Financial, Inc. (“Brighthouse Financial” or the “Company”) (Nasdaq: BHF) announced that today its Board of Directors (the “Board”) appointed Michael J.

Key Points: 
  • Brighthouse Financial, Inc. (“Brighthouse Financial” or the “Company”) (Nasdaq: BHF) announced that today its Board of Directors (the “Board”) appointed Michael J.
  • (“Mike”) Inserra and Lizabeth H. Zlatkus as independent members of the Board.
  • Mr. Inserra and Ms. Zlatkus were also each designated by the Board as an “audit committee financial expert” under applicable U.S. Securities and Exchange Commission rules and appointed to serve on the Audit Committee.
  • “Mike and Lizabeth each bring valuable experience in the insurance and financial services industries, along with strong leadership skills, financial expertise and deep knowledge of operations and risk management,” said C. Edward (“Chuck”) Chaplin, chairman of the Board, Brighthouse Financial.

Court Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict Litigation

Retrieved on: 
星期四, 二月 29, 2024
Indivior, Court, Competition law, District court, MDL

RICHMOND, Va., Feb. 29, 2024 /PRNewswire/ -- Indivior PLC (LSE: INDV; Nasdaq: INDV), a leading addiction treatment company, today announced that its subsidiary, Indivior Inc., has received final Court approval for its settlement with the Direct Purchaser class, concluding the anti-trust multi-district litigation ("MDL") matter.

Key Points: 
  • RICHMOND, Va., Feb. 29, 2024 /PRNewswire/ -- Indivior PLC (LSE: INDV; Nasdaq: INDV), a leading addiction treatment company, today announced that its subsidiary, Indivior Inc., has received final Court approval for its settlement with the Direct Purchaser class, concluding the anti-trust multi-district litigation ("MDL") matter.
  • On October 22, 2023, Indivior Inc. entered into a settlement agreement with the remaining Direct Purchaser class for $385m.
  • On February 27, 2024, the United States District Court for the Eastern District of Pennsylvania entered an order granting final judgement and order of dismissal approving the Direct Purchaser class settlement and dismissing the Direct Purchaser class claims.
  • This ruling concludes the Antitrust MDL.

Indivior Announces Q4 / FY 2023 Financial Results

Retrieved on: 
星期四, 二月 22, 2024
Indivior, EST, Webcast

SLOUGH, United Kingdom and RICHMOND, Va., Feb. 22, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending December 31, 2023.

Key Points: 
  • SLOUGH, United Kingdom and RICHMOND, Va., Feb. 22, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending December 31, 2023.
  • The earnings release, investor presentation and webcast are available at www.indivior.com .
  • There will be a live webcast presentation at 13:00 BST (8:00 am EST) hosted by Mark Crossley, CEO.
  • Participants may access the presentation telephonically by registering with the following link: https://register.vevent.com/register/BI7bc18cb84a3744af8c4ad20973d37a5a

Indivior Announces Q4 / FY 2023 Financial Results

Retrieved on: 
星期四, 二月 22, 2024
Indivior, EST, Webcast

SLOUGH, United Kingdom and RICHMOND, Va., Feb. 22, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending December 31, 2023.

Key Points: 
  • SLOUGH, United Kingdom and RICHMOND, Va., Feb. 22, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending December 31, 2023.
  • The earnings release, investor presentation and webcast are available at www.indivior.com .
  • There will be a live webcast presentation at 13:00 BST (8:00 am EST) hosted by Mark Crossley, CEO.
  • Participants may access the presentation telephonically by registering with the following link: https://register.vevent.com/register/BI7bc18cb84a3744af8c4ad20973d37a5a

Calliditas announces additions to the management team

Retrieved on: 
星期五, 十二月 1, 2023
Transfer, Indivior, New product development, Corporation, Sustainability, General counsel, AstraZeneca, Quality assurance, CALT, Pharmacy, CET, Allan Nyom, University, Endo International, Person, CMC, Doctor of Philosophy, Gettysburg College, Management, Pfizer

STOCKHOLM, Dec. 1, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ('Calliditas') today announced that the company has added a new member to its management team, Head of Technical Operations Lars Stubberud.

Key Points: 
  • STOCKHOLM, Dec. 1, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ('Calliditas') today announced that the company has added a new member to its management team, Head of Technical Operations Lars Stubberud.
  • Brian Gorman is an accomplished legal and business executive with more than 20 years of experience advising corporate boards and executive management teams of life science companies.
  • He joins Calliditas after having served most recently as Executive Vice President, Corporate Development & General Counsel at Opiant Pharmaceuticals, which was acquired by Indivior PLC.
  • We welcome Brian to the team and look forward to working with him as we embark on the next chapter of our journey," said Renée Aguiar-Lucander, CEO Calliditas.

Calliditas announces additions to the management team

Retrieved on: 
星期五, 十二月 1, 2023
Transfer, Indivior, New product development, Corporation, Sustainability, General counsel, AstraZeneca, Quality assurance, CALT, Pharmacy, CET, Allan Nyom, University, Endo International, Person, CMC, Doctor of Philosophy, Gettysburg College, Management, Pfizer

STOCKHOLM, Dec. 1, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ('Calliditas') today announced that the company has added a new member to its management team, Head of Technical Operations Lars Stubberud.

Key Points: 
  • STOCKHOLM, Dec. 1, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ('Calliditas') today announced that the company has added a new member to its management team, Head of Technical Operations Lars Stubberud.
  • Brian Gorman is an accomplished legal and business executive with more than 20 years of experience advising corporate boards and executive management teams of life science companies.
  • He joins Calliditas after having served most recently as Executive Vice President, Corporate Development & General Counsel at Opiant Pharmaceuticals, which was acquired by Indivior PLC.
  • We welcome Brian to the team and look forward to working with him as we embark on the next chapter of our journey," said Renée Aguiar-Lucander, CEO Calliditas.

Opioid Use Disorder Market Insights, Epidemiology and Forecasts, 2019-2032: Focus on United States, Germany, Spain, Italy, France, United Kingdom, and Japan - ResearchAndMarkets.com

Retrieved on: 
星期五, 十月 27, 2023
General Health, Pharmaceutical, Health, FDA, United Kingdom, Naltrexone, Epidemiology, Naloxone, Expert Opinion on Emerging Drugs, Therapy, Medicare, Organ donation after medical assistance in dying, Opioid use disorder, VIVITROL, Community Living Assistance Services and Supports Act, OTP, Disease, Methadone, OUD, Growth, Medicaid, COVID-19, Drug, EU4, Vaccine, Cereal, Pharmaceutical industry, Medical device, Dentistry, Health insurance, Health care, Buprenorphine, Indivior

The "Opioid Use Disorder (OUD)" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Key Points: 
  • The "Opioid Use Disorder (OUD)" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
  • The Opioid Use Disorder (OUD) market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Opioid Use Disorder (OUD) market size from 2019 to 2032.
  • Opioid Use Disorder (OUD) Treatment FDA-approved drugs such as Buprenorphine, methadone, and naltrexone have proven effective in treating Opioid Use Disorder, decreasing overdose rates.
  • Which type of Opioid Use Disorder (OUD), as per severity, is the largest contributor to the Opioid Use Disorder (OUD) patient pool?

Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals

Retrieved on: 
星期三, 十月 11, 2023
LAI, Drug development, Opioid use disorder, Central nervous system, Buprenorphine, Safety, Conditional sentence, OUD, CNS, Justice, Patient, Pharmaceutical industry, Daminozide, Indivior

RICHMOND, Va., Oct. 11, 2023 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV), a leading addiction treatment company, today announced that it has gained exclusive global rights to develop, manufacture, and commercialize Alar Pharmaceuticals Inc.'s ("Alar") portfolio of long-acting injectable formulations that release a prodrug1 of buprenorphine at varying durations, including its lead long-acting injectable ("LAI") candidate, ALA-1000.

Key Points: 
  • Under the agreement with Alar, Indivior will pay $10 million to secure exclusive global rights (except in China, Hong Kong, Taiwan and Macau) to develop, manufacture and commercialize ALA-1000 and Alar's future buprenorphine-based LAI product candidates.
  • The $10 million payment is in addition to an initial $5 million option payment made by Indivior to Alar in Q1.
  • Alar is entitled to potential milestone payments if various developmental, regulatory, and commercial goals are achieved.
  • Alar has been granted composition of matter and formulation patents for ALA-1000 covering sustained-release buprenorphine formulations with expiry in 2037 and 2039.